Add-on treatment with DeltEx DRI, a cell therapy being developed by In8bio, may help prolong survival in people with glioblastoma, an aggressive form of…

A combination of the immune-modulating treatments Lymphir (denileukin diftitox) and Keytruda (pembrolizumab) led to clinical benefit in nearly half of evaluable patients in an exploratory clinical…

Treatment with a regimen based on the experimental therapy mezigdomide reduced the risk of disease progression or death by more than 50% compared with standard…